Treatment and prognosis of 76 patients with gallbladder cancer: a single-center retrospective study
10.3760/cma.j.issn.1007-8118.2016.11.012
- VernacularTitle:胆囊癌患者的治疗与预后:单中心76例回顾性分析
- Author:
Xiaosong XIANG
;
Xiangyang LI
;
Xin ZHAO
;
Peng ZHENG
;
Yannian LIAO
;
Donghu LI
;
Wu JI
- Keywords:
Gallbladder cancer;
Surgery treatment;
Chemotherapy;
Prognostic factors
- From:
Chinese Journal of Hepatobiliary Surgery
2016;22(11):761-765
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate effective treatment modalities and the related factors influencing prognosis of patients with gallbladder cancer.Methods The clinical data of 76 gallbladder carcinoma patients admitted to the Department of General Surgery,PLA Nanjing General Hospital from January 2005 to October 2015 were analyzed retrospectively.Follow-up was carried out via telephone or outpatient service until January 2016.Cox regression and Kaplan-Meier models were performed for survival analysis.Results 69 patients were treated with surgery and/or postoperative adjuvant chemotherapy.The remaining 7 patients with liver or distant metastases who did not undergo surgery received chemotherapy.24 patients died from cancer relapse,37 patients died from disease progression after giving up treatment,and 7 patients were lost to follow-up.The remaining 8 patients were still alive at the time of follow-up.The depth of cancer invasion (HR =2.736),the type surgical procedure (HR =2.207),and adjuvant chemotherapy (HR =0.603) were significant impact factors of survival for GBC patients.Adjuvant chemotherapy was a protective factor.The average survival in the chemotherapy-naive group was (10.6 ± 1.9) months,the single chemotherapy group (18.5 ± 2.8) months,and the combined chemotherapy group (26.9 ± 6.4) months.There were no significant differences among these groups.Conclusions The depth of cancer invasion,types of surgical procedure particularly radical cholecystectomy,and adjuvant chemotherapy were significant factors of survival in patients with GBC.Radical cholecystectomy combined with arterial and intravenous chemotherapy using gemcitabine and oxaliplatin showed benefits in survival in GBC patients.
